Ipilimumab
ثبت نشده
چکیده
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II for lymphoma and non-small cell lung cancer in the US and other areas of the world. This review discusses the key development milestones and therapeutic trials on this drug to date.
منابع مشابه
Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis
OBJECTIVES We aimed to compare and rank the effects of 9 immune checkpoint inhibitor-related therapies for treating advanced melanoma. METHODS We searched Pubmed, Cochrane databases, Web of Science, and ClinicalTrials.gov for randomized controlled trials of the immune checkpoint inhibitor-related treatments for advanced melanoma. Analysis was done on a Bayesian framework. RESULTS Twelve tri...
متن کاملPatterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the effic...
متن کاملEfficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
BACKGROUND Anti-PD-1 monoclonal antibodies, nivolumab and pembrolizumab, and anti-CTLA-4 antibody ipilimumab are being in clinic trials to treat melanoma. Here, we performed a meta-analysis to evaluate the efficacy and toxicity of them against advanced melanoma. METHODS Eleven reports from 6 randomized control trials on treating metastatic melanoma, which were divided into 3 subgroups, nivolu...
متن کاملRemarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical successes in management of malignant tumors. As the first monoclonal antibody targeting immune checkpoint molecules entered into clinics, the molecular basis of ipilimumab-based anti-CTLA-4 blockade has not yet been fully understood. In the present study, we report the complex structure of ipilimumab and CTLA-...
متن کاملHealth related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
BACKGROUND In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial's 12 week treatment induction period. METHODS The Phase III c...
متن کاملIpilimumab and radiation therapy for melanoma brain metastases
Ipilimumab, an antibody that enhances T-cell activation, may augment immunogenicity of tumor cells that are injured by radiation therapy. We hypothesized that patients with melanoma brain metastasis treated with both ipilimumab and radiotherapy would have improved overall survival, and that the sequence of treatments may affect disease control in the brain. We analyzed the clinical and radiogra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2010